These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38523538)

  • 1. Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems.
    Wen J; Xiao Y; Zhao M; Yang C; Hu W
    Curr Drug Metab; 2024; 25(2):174-177. PubMed ID: 38523538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics.
    Iwasaki K
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):328-35. PubMed ID: 17965516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro.
    Han M; Zhang X; Ye Z; Wang J; Qian J; Hu G; Cai J
    Chem Biol Interact; 2021 Dec; 350():109700. PubMed ID: 34648813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.
    Vermeer LM; Isringhausen CD; Ogilvie BW; Buckley DB
    Drug Metab Dispos; 2016 Mar; 44(3):453-9. PubMed ID: 26668209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
    Mueck W; Kubitza D; Becka M
    Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.
    Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G
    Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Inhibition of CYP3A4 by Voriconazole and Clarithromycin Influences Tacrolimus Pharmacokinetics: Case Series Study.
    Hirai T; Ino K; Ikejiri M; Tawara I; Iwamoto T
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):889-893. PubMed ID: 35978155
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
    Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
    Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation.
    Vavić N; Rančić N; Cikota-Aleksić B; Magić Z; Cimeša J; Obrenčević K; Radojević M; Mikov M; Dragojević-Simić V
    Vojnosanit Pregl; 2016 Jul; 73(7):663-7. PubMed ID: 29314799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
    Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
    J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole.
    Floren LC; Bekersky I; Benet LZ; Mekki Q; Dressler D; Lee JW; Roberts JP; Hebert MF
    Clin Pharmacol Ther; 1997 Jul; 62(1):41-9. PubMed ID: 9246018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations.
    Barter ZE; Perrett HF; Yeo KR; Allorge D; Lennard MS; Rostami-Hodjegan A
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):516-32. PubMed ID: 21104927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
    Zahno A; Brecht K; Bodmer M; Bur D; Tsakiris DA; Krähenbühl S
    Br J Pharmacol; 2010 Sep; 161(2):393-404. PubMed ID: 20735423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of clarithromycin on the pharmacokinetics of tacrolimus and expression of CYP3A4 and P-glycoprotein in rats.
    Wen J; ChenYang ; Zhao M; Hu W; Xiao YW
    Fundam Clin Pharmacol; 2023 Aug; 37(4):843-848. PubMed ID: 36811298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole.
    Chandel N; Aggarwal PK; Minz M; Sakhuja V; Kohli KK; Jha V
    Pharmacogenet Genomics; 2009 Jun; 19(6):458-63. PubMed ID: 19384264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
    Sun JY; Xu ZJ; Sun F; Guo HL; Ding XS; Chen F; Xu J
    Curr Pharm Des; 2018; 24(24):2765-2773. PubMed ID: 30156148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
    Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
    Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane Interactions, Ligand-Dependent Dynamics, and Stability of Cytochrome P4503A4 in Lipid Nanodiscs.
    Treuheit NA; Redhair M; Kwon H; McClary WD; Guttman M; Sumida JP; Atkins WM
    Biochemistry; 2016 Feb; 55(7):1058-69. PubMed ID: 26814638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.